Vital Therapies Stock Price, News & Analysis (NASDAQ:VTL)

$5.30 +0.60 (+12.77 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$4.70
Today's Range$4.65 - $5.45
52-Week Range$2.25 - $6.70
Volume145,337 shs
Average Volume179,255 shs
Market Capitalization$202.60 million
P/E Ratio-3.93
Dividend YieldN/A
Beta4.76

About Vital Therapies (NASDAQ:VTL)

Vital Therapies logoVital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.

Receive VTL News and Ratings via Email

Sign-up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTL
CUSIPN/A
Phone858-673-6840

Debt

Debt-to-Equity RatioN/A
Current Ratio8.26%
Quick Ratio8.26%

Price-To-Earnings

Trailing P/E Ratio-3.92589684520855
Forward P/E Ratio-4.21
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.82 per share
Price / Book2.91

Profitability

Trailing EPS($1.35)
Net Income$-40,960,000.00
Net MarginsN/A
Return on Equity-70.76%
Return on Assets-64.35%

Miscellaneous

Employees87
Outstanding Shares42,210,000

Vital Therapies (NASDAQ:VTL) Frequently Asked Questions

What is Vital Therapies' stock symbol?

Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."

How were Vital Therapies' earnings last quarter?

Vital Therapies Inc (NASDAQ:VTL) issued its quarterly earnings results on Wednesday, October, 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.02. During the same quarter in the prior year, the business earned ($0.32) earnings per share. View Vital Therapies' Earnings History.

When will Vital Therapies make its next earnings announcement?

Vital Therapies is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Vital Therapies.

Where is Vital Therapies' stock going? Where will Vital Therapies' stock price be in 2018?

2 brokerages have issued twelve-month price objectives for Vital Therapies' shares. Their predictions range from $6.00 to $6.00. On average, they anticipate Vital Therapies' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Vital Therapies.

Who are some of Vital Therapies' key competitors?

Who are Vital Therapies' key executives?

Vital Therapies' management team includes the folowing people:

  • Faheem Hasnain, Chairman of the Board (Age 58)
  • Russell J. Cox, Chief Executive Officer, Director (Age 54)
  • Michael V. Swanson M.B.A., Chief Financial Officer (Age 55)
  • Robert A. Ashley, Executive Vice President, Chief Technical Officer (Age 57)
  • Duane D Nash M.D., Executive Vice President, Chief Business Officer (Age 46)
  • Aron P. Stern M.B.A., Chief Administrative Officer (Age 61)
  • Andrew Henry, Vice President - Clinical Operations (Age 50)
  • Andrea Loewen-Rodriguez, Vice President - Regulatory Affairs and Quality Assurance (Age 47)
  • Richard Murawski, Vice President - Manufacturing (Age 66)
  • John Michael Dunn, General Counsel, Secretary (Age 63)

Who owns Vital Therapies stock?

Vital Therapies' stock is owned by many different of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (6.93%), BlackRock Inc. (2.35%), Millennium Management LLC (0.59%), Geode Capital Management LLC (0.46%), Renaissance Technologies LLC (0.16%) and Citadel Advisors LLC (0.09%). Company insiders that own Vital Therapies stock include Duane Nash, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Institutional Ownership Trends for Vital Therapies.

Who sold Vital Therapies stock? Who is selling Vital Therapies stock?

Vital Therapies' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Raymond James & Associates. View Insider Buying and Selling for Vital Therapies.

Who bought Vital Therapies stock? Who is buying Vital Therapies stock?

Vital Therapies' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Citadel Advisors LLC, BlueCrest Capital Management Ltd, Two Sigma Investments LP, Goldman Sachs Group Inc., Bank of Montreal Can and Geode Capital Management LLC. Company insiders that have bought Vital Therapies stock in the last two years include Duane Nash, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Insider Buying and Selling for Vital Therapies.

How do I buy Vital Therapies stock?

Shares of Vital Therapies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vital Therapies' stock price today?

One share of Vital Therapies stock can currently be purchased for approximately $5.30.

How big of a company is Vital Therapies?

Vital Therapies has a market capitalization of $202.60 million. The company earns $-40,960,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Vital Therapies employs 87 workers across the globe.

How can I contact Vital Therapies?

Vital Therapies' mailing address is 15010 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]


MarketBeat Community Rating for Vital Therapies (VTL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  284
MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vital Therapies (NASDAQ:VTL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$8.00$8.00
Price Target Upside: 25.00% upside25.00% upside207.69% upside207.69% upside

Vital Therapies (NASDAQ:VTL) Consensus Price Target History

Price Target History for Vital Therapies (NASDAQ:VTL)

Vital Therapies (NASDAQ:VTL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Raymond James FinancialReiterated RatingBuyHighView Rating Details
3/10/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
1/2/2017Canaccord GenuitySet Price TargetBuy$10.00N/AView Rating Details
3/14/2016Credit Suisse GroupReiterated RatingNeutral$9.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Vital Therapies (NASDAQ:VTL) Earnings History and Estimates Chart

Earnings by Quarter for Vital Therapies (NASDAQ:VTL)

Vital Therapies (NASDAQ VTL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.31)N/AView Earnings Details
10/25/2017Q3 2017($0.32)($0.30)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.30)($0.29)ViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)ViewListenView Earnings Details
3/7/2017Q4 2016($0.36)($0.37)ViewListenView Earnings Details
11/3/2016Q316($0.32)($0.32)ViewN/AView Earnings Details
8/2/2016Q216($0.33)($0.30)ViewN/AView Earnings Details
5/9/2016Q1($0.28)($0.31)ViewN/AView Earnings Details
3/8/2016Q415($0.42)($0.34)ViewN/AView Earnings Details
11/5/2015Q315($0.58)($0.51)ViewListenView Earnings Details
7/30/2015Q215($0.62)($0.63)ViewListenView Earnings Details
5/12/2015Q1($0.62)($0.62)ViewListenView Earnings Details
3/19/2015Q414($0.59)($0.59)ViewListenView Earnings Details
11/13/2014Q314($0.63)($0.59)ViewN/AView Earnings Details
8/6/2014Q214($0.04)($0.91)ViewN/AView Earnings Details
6/3/2014($0.54)($24.49)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vital Therapies (NASDAQ:VTL) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.26 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS

Dividends

Dividend History for Vital Therapies (NASDAQ:VTL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Vital Therapies (NASDAQ VTL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.60%
Institutional Ownership Percentage: 25.18%
Insider Trades by Quarter for Vital Therapies (NASDAQ:VTL)
Institutional Ownership by Quarter for Vital Therapies (NASDAQ:VTL)

Vital Therapies (NASDAQ VTL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2017Muneer A SatterDirectorBuy100,000$5.48$548,000.00View SEC Filing  
12/11/2017Muneer A SatterDirectorBuy150,000$4.89$733,500.00View SEC Filing  
12/7/2017Muneer A SatterDirectorBuy50,000$4.77$238,500.00View SEC Filing  
9/14/2017Muneer A SatterDirectorBuy130,000$4.01$521,300.00View SEC Filing  
9/13/2017Jean Jacques BienaimeDirectorBuy10,000$4.00$40,000.0065,119View SEC Filing  
9/8/2017Muneer A SatterDirectorBuy50,000$3.53$176,500.00View SEC Filing  
6/14/2017John Michael DunnGeneral CounselBuy2,500$3.09$7,725.009,485View SEC Filing  
6/14/2017Muneer A SatterDirectorBuy20,000$3.07$61,400.00View SEC Filing  
6/14/2017Terence E WintersChairmanBuy10,000$3.10$31,000.00194,966View SEC Filing  
6/13/2017Muneer A SatterDirectorBuy10,000$3.03$30,300.00View SEC Filing  
6/12/2017Muneer A SatterDirectorBuy30,000$3.11$93,300.00View SEC Filing  
6/9/2017Robert A AshleyInsiderBuy2,000$3.18$6,360.002,000View SEC Filing  
6/8/2017Duane NashPresidentBuy3,900$3.12$12,168.008,224View SEC Filing  
6/7/2017Muneer A SatterDirectorBuy20,000$3.20$64,000.00View SEC Filing  
6/6/2017Muneer A SatterDirectorBuy10,000$3.19$31,900.00View SEC Filing  
3/27/2017Muneer A SatterDirectorBuy3,750,000$4.00$15,000,000.00View SEC Filing  
8/12/2016Faheem HasnainDirectorBuy118,243$5.92$699,998.56122,743View SEC Filing  
10/28/2015Muneer A SatterDirectorBuy400,000$5.50$2,200,000.00View SEC Filing  
10/26/2015Cheryl CohenDirectorBuy3,500$7.17$25,095.00View SEC Filing  
10/26/2015John Michael DunnGeneral CounselBuy9,385$6.81$63,911.859,385View SEC Filing  
9/10/2015Jean Jacques BienaimeDirectorBuy14,000$3.08$43,120.0039,119View SEC Filing  
10/10/2014Terence E WintersCEOBuy1,360$14.86$20,209.60View SEC Filing  
10/8/2014Duane NashInsiderBuy100$17.50$1,750.00View SEC Filing  
10/8/2014Lowell SearsDirectorBuy1,429$17.50$25,007.50View SEC Filing  
6/3/2014Muneer A SatterDirectorBuy14,500$13.16$190,820.00View SEC Filing  
4/23/2014Muneer A SatterDirectorBuy360,966$12.00$4,331,592.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vital Therapies (NASDAQ VTL) News Headlines

Source:
DateHeadline
Vital Therapies Inc (VTL) Expected to Announce Earnings of -$0.30 Per ShareVital Therapies Inc (VTL) Expected to Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - February 18 at 7:20 PM
-$0.30 Earnings Per Share Expected for Vital Therapies Inc (VTL) This Quarter-$0.30 Earnings Per Share Expected for Vital Therapies Inc (VTL) This Quarter
www.americanbankingnews.com - February 1 at 9:12 PM
Vital Therapies (VTL) Stock Rating Upgraded by BidaskClubVital Therapies (VTL) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 1 at 12:30 AM
Contrasting Halozyme Therapeutics (HALO) and Vital Therapies (VTL)Contrasting Halozyme Therapeutics (HALO) and Vital Therapies (VTL)
www.americanbankingnews.com - January 21 at 1:16 AM
Vital Therapies Inc (VTL) Expected to Post Earnings of -$0.30 Per ShareVital Therapies Inc (VTL) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - January 15 at 9:14 PM
Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - January 5 at 10:40 AM
 Brokerages Expect Vital Therapies Inc (VTL) to Post -$0.30 EPS Brokerages Expect Vital Therapies Inc (VTL) to Post -$0.30 EPS
www.americanbankingnews.com - December 30 at 1:24 AM
Vital Therapies, Inc. (VTL) Receives Average Rating of "Hold" from BrokeragesVital Therapies, Inc. (VTL) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 19 at 3:36 AM
Insider Buying: Vital Therapies, Inc. (VTL) Director Buys 100,000 Shares of StockInsider Buying: Vital Therapies, Inc. (VTL) Director Buys 100,000 Shares of Stock
www.americanbankingnews.com - December 14 at 8:52 PM
 Analysts Expect Vital Therapies, Inc. (VTL) to Announce -$0.30 EPS Analysts Expect Vital Therapies, Inc. (VTL) to Announce -$0.30 EPS
www.americanbankingnews.com - December 12 at 11:14 PM
Insider Buying: Vital Therapies, Inc. (VTL) Director Purchases 50,000 Shares of StockInsider Buying: Vital Therapies, Inc. (VTL) Director Purchases 50,000 Shares of Stock
www.americanbankingnews.com - December 11 at 8:50 PM
Vital Therapies, Inc. (VTL) Director Muneer A. Satter Buys 150,000 SharesVital Therapies, Inc. (VTL) Director Muneer A. Satter Buys 150,000 Shares
www.americanbankingnews.com - December 11 at 8:26 PM
Vital Therapies Added to NASDAQ Biotechnology IndexVital Therapies Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 11 at 11:10 AM
Vital Therapies (VTL) Earns Buy Rating from Raymond James FinancialVital Therapies (VTL) Earns Buy Rating from Raymond James Financial
www.americanbankingnews.com - December 6 at 5:00 PM
 Analysts Expect Vital Therapies, Inc. (VTL) to Post -$0.30 EPS Analysts Expect Vital Therapies, Inc. (VTL) to Post -$0.30 EPS
www.americanbankingnews.com - November 25 at 3:24 AM
Vital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by AnalystsVital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 24 at 3:56 AM
Analyzing Stemline Therapeutics (STML) and Vital Therapies (VTL)Analyzing Stemline Therapeutics (STML) and Vital Therapies (VTL)
www.americanbankingnews.com - November 23 at 11:40 PM
ValuEngine Downgrades Vital Therapies, Inc. (VTL) to Strong SellValuEngine Downgrades Vital Therapies, Inc. (VTL) to Strong Sell
www.americanbankingnews.com - November 18 at 12:04 AM
Vital Therapies to Webcast Presentation at Upcoming Investor ConferenceVital Therapies to Webcast Presentation at Upcoming Investor Conference
feeds.benzinga.com - November 8 at 8:50 AM
Financial Analysis: Vital Therapies (VTL) & Xenetic Biosciences (XBIO)Financial Analysis: Vital Therapies (VTL) & Xenetic Biosciences (XBIO)
www.americanbankingnews.com - November 7 at 1:28 AM
-$0.30 Earnings Per Share Expected for Vital Therapies, Inc. (VTL) This Quarter-$0.30 Earnings Per Share Expected for Vital Therapies, Inc. (VTL) This Quarter
www.americanbankingnews.com - November 6 at 3:22 AM
Vital Therapies (VTL) versus Its Rivals Head-To-Head ContrastVital Therapies (VTL) versus Its Rivals Head-To-Head Contrast
www.americanbankingnews.com - October 31 at 3:06 PM
Vital Therapies, Inc. (VTL) Downgraded to Sell at Zacks Investment ResearchVital Therapies, Inc. (VTL) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - October 31 at 11:53 AM
Vital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by BrokeragesVital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 30 at 1:22 AM
Edited Transcript of VTL earnings conference call or presentation 25-Oct-17 8:30pm GMTEdited Transcript of VTL earnings conference call or presentation 25-Oct-17 8:30pm GMT
finance.yahoo.com - October 28 at 8:34 AM
Vital Therapies, Inc. (VTL) Announces  Earnings ResultsVital Therapies, Inc. (VTL) Announces Earnings Results
www.americanbankingnews.com - October 26 at 9:06 PM
Vital Therapies, Inc. (VTL) Set to Announce Earnings on WednesdayVital Therapies, Inc. (VTL) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:36 AM
ValuEngine Upgrades Vital Therapies, Inc. (VTL) to "Sell"ValuEngine Upgrades Vital Therapies, Inc. (VTL) to "Sell"
www.americanbankingnews.com - October 21 at 9:52 AM
 Analysts Anticipate Vital Therapies, Inc. (VTL) Will Post Earnings of -$0.30 Per Share Analysts Anticipate Vital Therapies, Inc. (VTL) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - October 17 at 12:52 PM
BidaskClub Upgrades Vital Therapies, Inc. (VTL) to Strong-BuyBidaskClub Upgrades Vital Therapies, Inc. (VTL) to Strong-Buy
www.americanbankingnews.com - October 5 at 11:20 PM
Vital Therapies, Inc. (VTL) Receives Consensus Rating of "Hold" from BrokeragesVital Therapies, Inc. (VTL) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 5 at 10:20 PM
Vital Therapies, Inc. (VTL) Stock Rating Lowered by Zacks Investment ResearchVital Therapies, Inc. (VTL) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 5 at 6:58 PM
Reviewing Vital Therapies (VTL) and The CompetitionReviewing Vital Therapies (VTL) and The Competition
www.americanbankingnews.com - October 5 at 12:16 AM
All You Need To Know About Vital Therapies Inc’s (VTL) RisksAll You Need To Know About Vital Therapies Inc’s (VTL) Risks
finance.yahoo.com - October 3 at 2:44 PM
Is It Too Late To Buy Vital Therapies Inc (VTL)?Is It Too Late To Buy Vital Therapies Inc (VTL)?
finance.yahoo.com - September 16 at 10:17 AM
Insider Buying: Vital Therapies, Inc. (VTL) Director Buys 10,000 Shares of StockInsider Buying: Vital Therapies, Inc. (VTL) Director Buys 10,000 Shares of Stock
www.americanbankingnews.com - September 14 at 11:56 PM
Vital Therapies, Inc. (VTL) Director Muneer A. Satter Purchases 130,000 SharesVital Therapies, Inc. (VTL) Director Muneer A. Satter Purchases 130,000 Shares
www.americanbankingnews.com - September 14 at 10:52 PM
Vital Therapies, Inc. (VTL) Director Buys $176,500.00 in StockVital Therapies, Inc. (VTL) Director Buys $176,500.00 in Stock
www.americanbankingnews.com - September 12 at 7:54 PM
Vital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor ConferenceVital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference
finance.yahoo.com - September 11 at 8:25 AM
Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of DirectorsVital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
feeds.benzinga.com - September 6 at 8:23 AM
Edited Transcript of VTL earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of VTL earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 5 at 8:24 AM
Vital Therapies Announces Second Quarter 2017 Financial ResultsVital Therapies Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 9:53 AM
Vital Therapies, Inc. (NASDAQ:VTL) Issues Quarterly  Earnings ResultsVital Therapies, Inc. (NASDAQ:VTL) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 4 at 12:50 AM
Vital Therapies, Inc. (VTL) Set to Announce Earnings on MondayVital Therapies, Inc. (VTL) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 24 at 8:43 AM
Vital Therapies, Inc. (VTL) Expected to Post Earnings of -$0.30 Per ShareVital Therapies, Inc. (VTL) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - July 13 at 12:22 AM
Vital Therapies reports 1Q lossVital Therapies reports 1Q loss
marketbeat.com - May 9 at 7:28 PM
VITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StatementVITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement
biz.yahoo.com - March 23 at 8:57 PM
VITAL THERAPIES INC Files SEC form 8-K, Other EventsVITAL THERAPIES INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 8:21 PM
Vital Therapies Announces Fourth Quarter and Full Year 2016 Financial ResultsVital Therapies Announces Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 8 at 12:24 AM
4:02 pm Vital Therapies misses by $0.014:02 pm Vital Therapies misses by $0.01
us.rd.yahoo.com - March 8 at 12:24 AM

SEC Filings

Vital Therapies (NASDAQ:VTL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vital Therapies (NASDAQ:VTL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vital Therapies (NASDAQ VTL) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.